Intellia Therapeutics Announces Executive Appointments
Ticker: NTLA · Form: 8-K · Filed: Jun 26, 2024 · CIK: 1652130
Sentiment: neutral
Topics: executive-appointment, personnel-change, compensation
Related Tickers: NTLA
TL;DR
Intellia beefs up leadership with new CSO & CMO appointments.
AI Summary
Intellia Therapeutics, Inc. announced on June 21, 2024, changes in its board of directors and executive compensation. Specifically, Dr. John Leonard has been appointed as Chief Scientific Officer, and Dr. Glenn Pierce has been appointed as Chief Medical Officer. The company also disclosed compensatory arrangements for these key officers.
Why It Matters
These appointments signal a strengthening of Intellia's scientific and medical leadership, potentially impacting the company's gene editing therapy development and clinical trial progress.
Risk Assessment
Risk Level: medium — Changes in key executive roles and compensatory arrangements can indicate strategic shifts or internal developments that may affect future performance.
Key Players & Entities
- Intellia Therapeutics, Inc. (company) — Registrant
- Dr. John Leonard (person) — Appointed Chief Scientific Officer
- Dr. Glenn Pierce (person) — Appointed Chief Medical Officer
- June 21, 2024 (date) — Date of earliest event reported
FAQ
Who were the key individuals appointed to new roles at Intellia Therapeutics?
Dr. John Leonard was appointed as Chief Scientific Officer and Dr. Glenn Pierce was appointed as Chief Medical Officer.
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is June 21, 2024.
What specific items are covered in this Form 8-K filing?
This filing covers the departure of directors or certain officers, election of directors, appointment of certain officers, compensatory arrangements of certain officers, Regulation FD Disclosure, and Financial Statements and Exhibits.
What is Intellia Therapeutics, Inc.'s principal executive office address?
The principal executive offices are located at 40 Erie Street, Suite 130, Cambridge, Massachusetts 02139.
What is the Commission File Number for Intellia Therapeutics, Inc.?
The Commission File Number for Intellia Therapeutics, Inc. is 001-37766.
Filing Stats: 1,680 words · 7 min read · ~6 pages · Grade level 11.4 · Accepted 2024-06-26 08:06:00
Key Financial Figures
- $0.0001 — ich registered Common Stock (Par Value $0.0001) NTLA The Nasdaq Global Market Ind
- $510,000 — eceive an initial annual base salary of $510,000 and will be eligible to earn an annual
- $100,000 — ill receive a one-time sign-on bonus of $100,000.00, which is subject to full or partial
- $1,680,000 — common stock with a grant date value of $1,680,000; (ii) a time-based restricted stock uni
- $840,000 — award with a grant date target value of $840,000; and (iv) a performance-based restricte
Filing Documents
- d822257d8k.htm (8-K) — 36KB
- d822257dex101.htm (EX-10.1) — 74KB
- d822257dex102.htm (EX-10.2) — 148KB
- d822257dex991.htm (EX-99.1) — 11KB
- g822257dsp55.jpg (GRAPHIC) — 4KB
- g822257dsp69.jpg (GRAPHIC) — 4KB
- g822257g0625232539747.jpg (GRAPHIC) — 4KB
- g822257g28f43.jpg (GRAPHIC) — 32KB
- 0001193125-24-168545.txt ( ) — 510KB
- ntla-20240621.xsd (EX-101.SCH) — 3KB
- ntla-20240621_lab.xml (EX-101.LAB) — 18KB
- ntla-20240621_pre.xml (EX-101.PRE) — 11KB
- d822257d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description of Exhibit 10.1 Employment Agreement between Intellia Therapeutics, Inc. and Edward Dulac 10.2 Intellia Therapeutics, Inc. 2024 Inducement Plan and forms of award agreements thereunder 99.1 Press Release dated June 26, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Intellia Therapeutics, Inc. Date: June 26, 2024 By: /s/ John M. Leonard Name: John M. Leonard Title: Chief Executive Officer and President